魯抗醫藥(600789.SH)擬投資建設頭孢類醫藥中間體技術升級改造項目
格隆匯4月17日丨魯抗醫藥(600789.SH)公佈,為優化企業產品結構,強化頭孢類產品鏈競爭優勢,提升新園區綜合競爭能力,公司擬投資1.746億元啟動頭孢類醫藥中間體技術升級改造項目,提升原料藥產品競爭力。
該項目擬在魯抗生物醫藥循環經濟產業園區建設。該項目共包含五個部分:合成車間、溶媒回收車間、輔助車間、控制車間、罐區。項目建設分兩期進行,一期建設為主生產線以及配套的溶媒回收、廢水處理系統;二期建設為產能擴充線及配套的副產品加工回用生產線。
項目建成後年可增加銷售收入約3.2億元,投資回收期約為9.76年。將進一步提升頭孢類系列產品的競爭力,為做大做強戰略原料藥產品打下堅實的基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.